Interestingly, etanercept and adalimumab downregulate trimetylation of H3K4, H3K27, H3K36, and H3K79, as well as acetylation of histone 3 and 4 at the promoter site of CCL2 (MCP-1) in monocytes which correlated with RA disease activity (43). This evidence concerns the gene CCL2 and rheumatoid arthritis.